SCHEMBL2491997

SCHEMBL2491997

CCCC(CC(C)C)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.68
AKR1A1 P14550 1/20 0.68
CHRM3 P20309 1/20 0.68
HTR2A P28223 1/20 0.68
HTR2C P28335 1/20 0.68
ADRA1A P35348 1/20 0.68
HRH1 P35367 1/20 0.68
DRD3 P35462 1/20 0.68
SLC6A3 Q01959 1/20 0.68
HDAC1 Q13547 1/20 0.68
HDAC2 Q92769 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
SLC1A2 P43004 5/20 0.63
SLC1A3 P43003 4/20 0.63
SLC1A1 P43005 4/20 0.63
GRIK1 P39086 3/20 0.63
GRIK2 Q13002 3/20 0.63
CPA1 P15085 1/20 0.50
CA2 P00918 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12611015 0.90 CHRM1 (0.83) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL1716831 0.86 SLC1A2 (0.66) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL2386631 0.84 CHRM1 (0.65) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL8939043 0.84 CHRM1 (0.65) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL27749943 0.84 CHRM1 (0.65) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL31544400 0.83 SLC1A2 (0.56) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL1411995 0.83 GRIK1 (0.68) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL2835497 0.83 GRIK1 (0.68) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL2831405 0.83 GRIK1 (0.68) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL2833540 0.83 GRIK1 (0.68) CHRM1AKR1A1CHRM3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4444108-B1 ALDEHYDE MIXTURES FOR FLAVOUR IMPROVEMENT SYMRISE AG (DE) 2025-09-10 EP claimed
EP-4161293-B1 FLAVOURING COMPOSITION WITH BALANCED TASTE PROFILE SYMRISE AG (DE) 2024-01-31 EP claimed
EP-4161291-B1 FLAVORING COMPOSITIONS FOR TASTE IMPROVEMENT SYMRISE AG (DE) 2023-11-01 EP claimed
EP-3088955-B1 RESIST COMPOSITION AND PATTERNING PROCESS SHINETSU CHEMICAL CO (JP) 2020-06-03 EP claimed
EP-3202876-B1 FIXED BED DECOLORIZATION PROCESS FOR UNSATURATED FATTY ACID ZHEJIANG MED XINCHANG PHARM (CN) 2019-07-31 EP claimed
EP-3024918-B1 MANGANESE CARBOXYLATES FOR PEROXYGEN ACTIVATION ARKEMA INC (US) 2019-07-03 EP claimed
EP-3032333-B1 SHRINK MATERIAL AND PATTERN FORMING PROCESS SHINETSU CHEMICAL CO (JP) 2017-05-24 EP claimed
EP-3032332-B1 SHRINK MATERIAL AND PATTERN FORMING PROCESS SHINETSU CHEMICAL CO (JP) 2017-04-05 EP claimed
US-20160168515-A1 MANGANESE CARBOXYLATES FOR PEROXYGEN ACTIVATION ARKEMA INC. 2016-06-16 US claimed
EP-3024918-A1 MANGANESE CARBOXYLATES FOR PEROXYGEN ACTIVATION Arkema, Inc. (US) 2016-06-01 EP claimed
WO-2015012879-A1 MANGANESE CARBOXYLATES FOR PEROXYGEN ACTIVATION ARKEMA INC. (US) 2015-01-29 WO claimed
EP-1853713-B1 Process for the isolation of polyhydroxyalkanoates (PHAs) from bacterial cells by solvent extraction PHB IND SA (BR) 2012-05-02 EP claimed
US-20050267168-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2005-12-01 US claimed
US-20030096802-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2003-05-22 US claimed
US-6201021-B1 TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES ONO PHARMACEUTICAL CO., LTD. (JP) 2001-03-13 US claimed
EP-0632008-B1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO (JP) 1998-02-04 EP claimed
EP-0632008-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1995-01-04 EP claimed
US-12448306-B2 Electrocatalytic bio-oil and wastewater treatment BATTELLE MEMORIAL INSTITUTE (US) 2025-10-21 US disclosed
CN-1186065-A Method for producing trimethylhydroquinone diester DAICEL CHEM (JP) 1998-07-01 CN disclosed
US-5576459-A Quaternary nitrogen or phosphorus chirates SACHEM, INC. (US) 1996-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267168-A1 Pentanoic acid derivatives FFAR3, FFAR1, HCAR3 CHRM1 93/4885AKR1A1 771/4885CHRM3 89/4885
US-20030096802-A1 Pentanoic acid derivatives FFAR3, FPR1, FPR3 CHRM1 84/4885AKR1A1 976/4885CHRM3 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.